Related Experiment Video
Updated: Sep 28, 2025
An Ex Vivo Tissue Culture Model for Fibrovascular Complications in Proliferative Diabetic Retinopathy
Published on: January 25, 2019
Reversible Retinopathy Associated with Fibroblast Growth Factor Receptor Inhibitor
Saagar N Patel1, Mona L Camacci1, Esther M Bowie1
1Department of Ophthalmology, Penn State College of Medicine, Hershey, Pennsylvania, USA.
Abstract:
We present a case of reversible, pseudovitelliform lesions while a patient was taking pembrolizumab (PDL-1 inhibitor) and erdafitinib (pan-fibroblast growth factor receptor inhibitor) outside of clinical trial protocols. A 61-year-old patient with 3 days of metamorphopsia was found to have pseudovitelliform lesions in both eyes 6 weeks after initiation of erdafitinib. After discontinuation of this drug, his visual complaints resolved and his lesions decreased on optical coherence tomography. To our knowledge, this is the first case depicting reversible macular lesions with use of this newly approved medication outside of clinical trial protocols.
Insights
A patient taking erdafitinib developed reversible pseudovitelliform lesions. Vision improved and lesions resolved after discontinuing this pan-fibroblast growth factor receptor inhibitor.
Area of Science:
- Ophthalmology
- Oncology
- Pharmacology
Background:
- Pembrolizumab (PD-1 inhibitor) and erdafitinib (pan-fibroblast growth factor receptor inhibitor) are used in cancer treatment.
- Drug-induced ocular side effects can impact patient vision and require careful monitoring.
Observation:
- A 61-year-old patient experienced metamorphopsia (distorted vision) lasting 3 days.
- Ophthalmic examination revealed bilateral pseudovitelliform macular lesions 6 weeks after starting erdafitinib therapy.
Findings:
- The patient's visual complaints and pseudovitelliform lesions resolved after discontinuing erdafitinib.
- Optical coherence tomography confirmed the decrease in macular lesions.
Implications:
- This case highlights the potential for erdafitinib to cause reversible macular abnormalities.
- Early recognition and drug discontinuation may prevent persistent visual impairment.
- Further research is needed to understand the mechanism and incidence of these ocular side effects.
